Crinetics CRNX 深 沪
等待开盘 05-12 09:30:00 美东时间
36.55
-0.885
-2.36%
华盛通- 最 高43.62
- 今 开37.48
- 成交量 202.26万股
- 最 低 35.595
- 昨 收 37.435
- 总市值 195.56万
- 52周最高 57.99
- 市盈率 静 --
- 换手率 3780.07%
- 52周最低 25.83
- 委 比 -45.99%
- 总股本 5.35万
- 历史最高 62.53
- 量 比 1.12
- 振 幅 21.44%
- 历史最低 1.10
- 每 手 1
- 风险率 7.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Crinetics Pharmaceuticals Submits Marketing Authorization Application in Brazil for Palsonify In Acromegaly
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced the submission of a Marketing Authorization Application (MAA) to Brazil's National Health Surveillance Agency (ANVISA) for PALSONIFY™ (paltusotine),
03-27 04:15
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
Preview: Crinetics Pharmaceuticals's Earnings
Crinetics Pharmaceuticals (NASDAQ:CRNX) is preparing to release its quarterly e...
02-26 00:02
Crinetics Pharmaceuticals Reveals $350M Proposed Public Offering of Common Stock
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) ("Crinetics"), a pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors,
01-06 05:03
Crinetics Experimental Pill Slashes Hormones In Rare Adrenal Disease Trial
Crinetics Pharmaceuticals reported positive topline results from Phase 2 studies of atumelnant for CAH and ACTH-dependent Cushing's syndrome.
01-06 00:00
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
2025-11-06 19:12
Crinetics飙升26.6%，其肢端肥大症治疗药物获FDA批准
制药企业Crinetics Pharmaceuticals(CRNX)早盘飙升26.6%，获得美国FDA对肢端肥大症治疗药物Palsonify的批准。批准基于成功的三期试验，产品计划于10月初上市。这标志着Crinetics在罕见病治疗领域的重要里程碑。 海量资讯、精准解读，尽在新浪财经APP 责任编辑：张俊 SF065
2025-09-26 22:57
Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025
Crinetics Pharmaceuticals will host its R&D Day event on June 26, 2025, in New York, discussing updates on its early-stage pipeline assets, portfolio strategy, and advancements in treating endocrine diseases.
2025-06-16 12:00
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals granted stock options and RSUs to 20 new non-executive employees under its 2021 Inducement Plan. Stock options total 74,000 shares with an exercise price of $33.08 and RSUs total 48,850, both vesting over four years. The awards align with Nasdaq Listing Rule 5635(c)(4) and are conditioned on continued employment.
2025-06-10 20:29
